<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/060C89E9-66C5-4F7B-B010-218C2A4B88D5"><gtr:id>060C89E9-66C5-4F7B-B010-218C2A4B88D5</gtr:id><gtr:name>Okairos</gtr:name><gtr:address><gtr:line1>Viale Citt? d'Europa, 679</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Wellcome Trust Centre for Human Genetics</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/060C89E9-66C5-4F7B-B010-218C2A4B88D5"><gtr:id>060C89E9-66C5-4F7B-B010-218C2A4B88D5</gtr:id><gtr:name>Okairos</gtr:name><gtr:address><gtr:line1>Viale Citt? d'Europa, 679</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/72056FF9-D3CE-4186-BD73-491ABDB4EA85"><gtr:id>72056FF9-D3CE-4186-BD73-491ABDB4EA85</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Draper</gtr:surname><gtr:orcidId>0000-0002-9415-1357</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/17719B3D-8D27-40E3-967A-65E55AE07A99"><gtr:id>17719B3D-8D27-40E3-967A-65E55AE07A99</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:surname>Hill</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700735"><gtr:id>944484F4-638A-4E31-AC7E-C07FFF86D777</gtr:id><gtr:title>Vectored Blood Stage Malaria Vaccine</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700735</gtr:grantReference><gtr:abstractText>Malaria is one of the greatest causes of infectious mortality globally but no vaccine is available. The blood-stage of the parasite?s life-cycle is the one that causes all the symptoms of disease and very often death. Many vaccines against this stage have been tested in clinical trials but always with disappointing results. However, all these vaccine comprised protein components of the parasite mixed with a chemical adjuvant designed to try and increase the immune response to the vaccine. Quite different types of vaccine are now showing promise in other diseases such as HIV/AIDS, tuberculosis and even the liver-stage of malaria. These vectored vaccines use a crippled safe virus to produce the malaria antigen inside the injection site of the vaccinee. This generates qualitatively and quantitatively different immune responses to protein/adjuvant vaccines.
 Using a rodent malaria model we have found excellent protection using such vectored vaccines against blood-stage malaria and have gone on to make the corresponding vectors that target the major human parasite Plasmodium falciparum. In this application we propose to test a pair of vectored vaccines against the blood-stage of malaria for the first time in humans. We will use a well developed and safe infectious mosquito biting procedure to test whether the vaccine is effective in volunteers. This study should provide a critical test of the possibility that such vectored vaccines could be useful in protecting people against the important blood-stage of malaria.</gtr:abstractText><gtr:technicalSummary>A highly effective vaccine against malaria should have a major impact on the global disease burden. Blood stage vaccines offer the prospect of substantially reducing rates of severe disease while allowing some natural immunity to develop. However, the development of protein/adjuvant vaccines against blood-stage malaria has proved very difficult. Following up evidence that cellular immunity against blood-stage parasites may contribute to protection, we have made the surprising observation that high level protection against rodent blood-stage malaria can be induced by vectored vaccines. In particular priming with an adenoviral vector and boosting with MVA, each encoding the P. yoelii MSP-1(42) antigen, induced high level protection with just two immunisations. This protection was largely antibody mediated but, additionally, vaccine-induced CD8 T cells reduced liver-stage parasite numbers. 
 
We have used the same vectors with a P. falciparum insert to generate antibody responses which have strong growth inhibitory activity against different strains of this parasite in in vitro assays. 
 
We propose to undertake the first clinical trial of a vectored blood-stage vaccine against malaria. The insert encodes both of the dimorphic variants of PfMSP1(42) and four more N-terminal conserved regions. A potent simian adenoviral vector, that avoids anti-vector immunity problems associated with human adenoviral vectors, will be used as a priming agent and MVA will be used to boost further both antibody and T cell responses. After dose optimisation in a phase I trial, efficacy will be assessed by sporozoite challenge and quantitation of parasite growth rates in vivo.
 
This proof-of-concept trial will assess the potential utility of leading vectored vaccines against blood-stage malaria, should allow evaluation of several assays as correlates of blood-stage protective immunity, and may point the way towards defining a highly effective multi-stage vectored malaria vaccine.</gtr:technicalSummary><gtr:fund><gtr:end>2010-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>748840</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Okairos</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Okairos blood-stage vaccine</gtr:description><gtr:id>0C01B7B9-34DD-43AE-8EBB-4B79630CF4C3</gtr:id><gtr:impact>The trial started recently and progress to date has been very good with satisfatory safety and immunogenicity.</gtr:impact><gtr:outcomeId>0F0254FCF80-1</gtr:outcomeId><gtr:partnerContribution>Okairos provided an adenoviral vector for generating the blood-stage vaccine contrust</gtr:partnerContribution><gtr:piContribution>We have done all the pre-clinical studies and undertaken the clinical trial</gtr:piContribution><gtr:sector>Private</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EMVDA European Malaria Vaccine Development Association (13.5m euros across 16 participants)</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>EDAEAB4C-19D8-458F-8C42-92DD4893AD8E</gtr:id><gtr:outcomeId>0BDBA6DFD300</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2006-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Career Development Fellowship - Dr Simon Draper</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>E50232FC-C566-441F-9C8B-E95AA4518E8F</gtr:id><gtr:outcomeId>J6mgNAhijDs0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A two component vectored vaccine encoding the P. falciparum MSP1 antigen comprising simian adenoviral and MVA vectors</gtr:description><gtr:id>B2604EE9-5862-48D3-817F-771A5ED7A792</gtr:id><gtr:impact>This is the first clinical trial of vectored vaccines designed to induce strong cell mediated immunity to the blood-stage of the malaria parasite's life-cycle.</gtr:impact><gtr:outcomeId>FA279F1E51F</gtr:outcomeId><gtr:stage>Refinement.  Clinical</gtr:stage><gtr:status>On hold</gtr:status><gtr:title>MSP1 vectored vaccine</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Simian adenoviral vector and MVA vectors of GMP grade suitable for immunisation against malaria</gtr:description><gtr:id>6CE66199-3A9E-416B-874F-DD4D7858E3EE</gtr:id><gtr:impact>Phase I safety and immunogenicity study progressing well.</gtr:impact><gtr:outcomeId>6BE85CCD285</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>GMP grade blood-stage MSP1 malaria vaccine</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>ECA9C7C0-84E0-48E4-AA8E-57C214F3B4BC</gtr:id><gtr:title>Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria.</gtr:title><gtr:parentPublicationTitle>Cell host &amp; microbe</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40d40b441e7b9e50b5b7a28e5fe12d96"><gtr:id>40d40b441e7b9e50b5b7a28e5fe12d96</gtr:id><gtr:otherNames>Draper SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1931-3128</gtr:issn><gtr:outcomeId>996FB73C1B9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04614CA3-8141-40C6-8135-4B8ECE54DF59</gtr:id><gtr:title>Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd5c2368c19fb2cae0c43f7f8bb1958c"><gtr:id>cd5c2368c19fb2cae0c43f7f8bb1958c</gtr:id><gtr:otherNames>Sheehy SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>T14U4Dqe2SQ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE0BBE62-4299-4902-8946-0D1E2C31EF6D</gtr:id><gtr:title>Effective induction of high-titer antibodies by viral vector vaccines.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40d40b441e7b9e50b5b7a28e5fe12d96"><gtr:id>40d40b441e7b9e50b5b7a28e5fe12d96</gtr:id><gtr:otherNames>Draper SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>4536233D44A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF12A283-DFDB-48C2-8245-50F1CC5F1BAD</gtr:id><gtr:title>Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76b171ee3c5bedb32926231c89f7e054"><gtr:id>76b171ee3c5bedb32926231c89f7e054</gtr:id><gtr:otherNames>Biswas S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5488df4f8ea395.47830247</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D43D1998-F3CB-4EBF-AE6C-CB2E73431A3A</gtr:id><gtr:title>Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd5c2368c19fb2cae0c43f7f8bb1958c"><gtr:id>cd5c2368c19fb2cae0c43f7f8bb1958c</gtr:id><gtr:otherNames>Sheehy SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16119_29_22363582</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFB8B9D6-DF65-413C-B3D8-A0F3F13AA62A</gtr:id><gtr:title>Challenges of assessing the clinical efficacy of asexual blood-stage Plasmodium falciparum malaria vaccines.</gtr:title><gtr:parentPublicationTitle>Human vaccines &amp; immunotherapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd5c2368c19fb2cae0c43f7f8bb1958c"><gtr:id>cd5c2368c19fb2cae0c43f7f8bb1958c</gtr:id><gtr:otherNames>Sheehy SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2164-5515</gtr:issn><gtr:outcomeId>pm_13035_25_23778312</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55EF2B0A-CD96-450F-913C-6F75DCE0F8EC</gtr:id><gtr:title>T cell responses induced by adenoviral vectored vaccines can be adjuvanted by fusion of antigen to the oligomerization domain of C4b-binding protein.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc38a3c8d7daa55241aa596afb1e2901"><gtr:id>cc38a3c8d7daa55241aa596afb1e2901</gtr:id><gtr:otherNames>Forbes EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16119_29_22984589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DB35D138-BB5A-4821-9272-9E02826DFFB1</gtr:id><gtr:title>Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infection.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c14f468562fffaa13dd59e4fc7fddc23"><gtr:id>c14f468562fffaa13dd59e4fc7fddc23</gtr:id><gtr:otherNames>Douglas AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_16119_29_23570846</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17BA50DA-2D3E-4902-BFAF-8068B2C9AE90</gtr:id><gtr:title>Blood-stage malaria vaccines - recent progress and future challenges.</gtr:title><gtr:parentPublicationTitle>Annals of tropical medicine and parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2546e47efb1bfb085a82655340383cb4"><gtr:id>2546e47efb1bfb085a82655340383cb4</gtr:id><gtr:otherNames>Goodman AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0003-4983</gtr:issn><gtr:outcomeId>Zfvk5kCpapr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A536F102-99ED-4AEC-AED2-ECA025FB17E6</gtr:id><gtr:title>Tailoring subunit vaccine immunogenicity: maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.</gtr:title><gtr:parentPublicationTitle>Vaccine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c14f468562fffaa13dd59e4fc7fddc23"><gtr:id>c14f468562fffaa13dd59e4fc7fddc23</gtr:id><gtr:otherNames>Douglas AD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0264-410X</gtr:issn><gtr:outcomeId>fgG3QvaqvTL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DA727BE2-912E-4DA7-8C34-25357260E847</gtr:id><gtr:title>Prime-boost vectored malaria vaccines: progress and prospects.</gtr:title><gtr:parentPublicationTitle>Human vaccines</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d3a980f9c391b7f04b390cf1765ebdd"><gtr:id>7d3a980f9c391b7f04b390cf1765ebdd</gtr:id><gtr:otherNames>Hill AV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1554-8600</gtr:issn><gtr:outcomeId>mdTqLLRtHcc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>024DE7AF-31A5-42F9-ABA5-B340E79A31C0</gtr:id><gtr:title>New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1.</gtr:title><gtr:parentPublicationTitle>Infection and immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2546e47efb1bfb085a82655340383cb4"><gtr:id>2546e47efb1bfb085a82655340383cb4</gtr:id><gtr:otherNames>Goodman AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0019-9567</gtr:issn><gtr:outcomeId>Lnp4kRFk9zW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4008BA7-737E-4177-83DB-5989C1E82790</gtr:id><gtr:title>Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b46faaea29d65e5176dd6a77eddc991"><gtr:id>2b46faaea29d65e5176dd6a77eddc991</gtr:id><gtr:otherNames>Elias SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_16119_29_23293353</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3DFF3FE-DCEC-4029-98C4-2E7B820FAF7F</gtr:id><gtr:title>ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd5c2368c19fb2cae0c43f7f8bb1958c"><gtr:id>cd5c2368c19fb2cae0c43f7f8bb1958c</gtr:id><gtr:otherNames>Sheehy SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>pm_16119_29_23089736</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1B21BDF3-9931-4BEE-84F2-D25CD67B28C5</gtr:id><gtr:title>Comparison of clinical and parasitological data from controlled human malaria infection trials.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/058c1ccbe665a5aaa6371b395f1d2b02"><gtr:id>058c1ccbe665a5aaa6371b395f1d2b02</gtr:id><gtr:otherNames>Roestenberg M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_16119_29_22701640</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>646C9FA5-AC8E-456B-9AB5-C616DB035914</gtr:id><gtr:title>Distinguishing malaria and influenza: early clinical features in controlled human experimental infection studies.</gtr:title><gtr:parentPublicationTitle>Travel medicine and infectious disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6c7171b7961f3deba4f707f92470fada"><gtr:id>6c7171b7961f3deba4f707f92470fada</gtr:id><gtr:otherNames>Lillie PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1477-8939</gtr:issn><gtr:outcomeId>pm_16119_29_22531678</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D70D3451-BDB0-4C28-93D6-6DABC9CC8F67</gtr:id><gtr:title>Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.</gtr:title><gtr:parentPublicationTitle>Immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2b46faaea29d65e5176dd6a77eddc991"><gtr:id>2b46faaea29d65e5176dd6a77eddc991</gtr:id><gtr:otherNames>Elias SC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0019-2805</gtr:issn><gtr:outcomeId>pm_540e154e154c5264b</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DB96430-6F45-43B2-91DC-CD7BF589A652</gtr:id><gtr:title>Recombinant viral-vectored vaccines expressing Plasmodium chabaudi AS apical membrane antigen 1: mechanisms of vaccine-induced blood-stage protection.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76b171ee3c5bedb32926231c89f7e054"><gtr:id>76b171ee3c5bedb32926231c89f7e054</gtr:id><gtr:otherNames>Biswas S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_16119_29_22504652</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>046B1AE6-A358-4276-8B2C-1A3C3903D998</gtr:id><gtr:title>Viruses as vaccine vectors for infectious diseases and cancer.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40d40b441e7b9e50b5b7a28e5fe12d96"><gtr:id>40d40b441e7b9e50b5b7a28e5fe12d96</gtr:id><gtr:otherNames>Draper SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1740-1526</gtr:issn><gtr:outcomeId>dqVCtMqbut7</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700735</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>